866-997-4948(US-Canada Toll Free)

Obsessive-Compulsive Disorder - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Jul 2017

Category :

Pharmaceutical

No. of Pages : 33 Pages

Obsessive-Compulsive Disorder - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obsessive-Compulsive Disorder - Pipeline Review, H2 2017, provides an overview of the Obsessive-Compulsive Disorder (Central Nervous System) pipeline landscape.

Obsessive-compulsive disorder (OCD) is characterized by unreasonable thoughts and fears (obsessions) that lead to do repetitive behaviors (compulsions). Symptoms include having repeated thoughts or images about many different things, such as fear of germs, dirt, or intruders, acts of violence, hurting loved ones, doing the same rituals over and over such as washing hands, locking and unlocking doors, counting, keeping unneeded items, or repeating the same steps again and again. Risk factor includes family history. Treatment includes antidepressants and psychiatric medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Obsessive-Compulsive Disorder - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Obsessive-Compulsive Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Obsessive-Compulsive Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Obsessive-Compulsive Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Preclinical and Discovery stages are 1, 6 and 1 respectively.

Obsessive-Compulsive Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Obsessive-Compulsive Disorder (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Obsessive-Compulsive Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Obsessive-Compulsive Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Obsessive-Compulsive Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Obsessive-Compulsive Disorder (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Obsessive-Compulsive Disorder (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Obsessive-Compulsive Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Obsessive-Compulsive Disorder - Overview
Obsessive-Compulsive Disorder - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Obsessive-Compulsive Disorder - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Obsessive-Compulsive Disorder - Companies Involved in Therapeutics Development
AbbVie Inc
Addex Therapeutics Ltd
Amorsa Therapeutics Inc
Omeros Corp
Obsessive-Compulsive Disorder - Drug Profiles
18-MC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADX-71743 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADX-88178 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluvoxamine maleate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HUF-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Autism Spectrum Disorders and Obsessive Compulsive Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target NMDA Receptor for Obsessive-Compulsive Disorder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Obsessive-Compulsive Disorder - Dormant Projects
Obsessive-Compulsive Disorder - Discontinued Products
Obsessive-Compulsive Disorder - Product Development Milestones
Featured News & Press Releases
Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction
Aug 02, 2007: Jazz Pharmaceuticals, Inc. Announces Submission of Complete Responses to FDA Approvable Letters for Luvox
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Obsessive-Compulsive Disorder, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Obsessive-Compulsive Disorder - Pipeline by AbbVie Inc, H2 2017
Obsessive-Compulsive Disorder - Pipeline by Addex Therapeutics Ltd, H2 2017
Obsessive-Compulsive Disorder - Pipeline by Amorsa Therapeutics Inc, H2 2017
Obsessive-Compulsive Disorder - Pipeline by Omeros Corp, H2 2017
Obsessive-Compulsive Disorder - Dormant Projects, H2 2017
Obsessive-Compulsive Disorder - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Obsessive-Compulsive Disorder, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *